◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › B › BION

BB Biotech AG (BION) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-16

BB Biotech AG (BION) operates in the Biotechnology industry and is headquartered in Küsnacht, Switzerland with about 10 employees. Its market capitalization is roughly CHF 3 billion. In the fiscal year ended 2025-12-31, BION reported CHF 587M in revenue and CHF 578M in net income.

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology.

Interactive charts & full statements →

BION Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	CHF 587M	CHF 82M	(CHF 200M)	(CHF 351M)
Net Income	CHF 578M	CHF 76M	(CHF 207M)	(CHF 358M)

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BION Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Total Revenue	CHF 462M	(CHF 17M)	CHF 475M	(CHF 94M)	(CHF 239M)
Net Income	CHF 451M	(CHF 21M)	CHF 472M	(CHF 100M)	(CHF 241M)

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BION Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Dividends Paid	(CHF 98M)	(CHF 110M)	(CHF 156M)	(CHF 212M)	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BION Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Dividends Paid	CHF 0M	(CHF 124M)	CHF 0M	CHF 0M	(CHF 98M)

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BION Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CHF 2.8B	CHF 2.4B	CHF 2.6B	CHF 3.1B	—
Total Liabilities	CHF 7M	CHF 121M	CHF 314M	CHF 367M	—

CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BION viewer.

Other Companies in Biotechnology

QURE · uniQure N.V. — $3 billion
2197 · Clover Biopharmaceuticals, Ltd. — $3 billion
ARQT · Arcutis Biotherapeutics, Inc. — $3 billion
IRON · Disc Medicine, Inc. — $3 billion
IOVA · Iovance Biotherapeutics, Inc. — $3 billion
TARS · Tarsus Pharmaceuticals, Inc. — $3 billion
IMNM · Immunome, Inc. — $3 billion
NRIX · Nurix Therapeutics, Inc. — $3 billion

← BIOA All “B” companies BIOV →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.